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Abstract:  Objective: The human MUC7 gene encodes a low-molecular-weight mucin glycoprotein that functions in 
lubrication/protection of epithelial surfaces of the oral cavity and respiratory tract. This study was designed to evaluate the 
effect of cigarette smoke extract (CSE), cigarette smoke (CS), and Pseudomonas aeruginosa lipopolysaccharide (LPS), 
either alone or in the combination, on MUC7 expression in vitro and in vivo. 
Materials and Methods: qRT-PCR was used to determine the levels of mucin gene transcription in the human lung 
carcinoma cell line NCI-H292 (in vitro) and MUC7 transgenic mouse tissues (in vivo). ELISA was used to assess mucin 
glycoprotein levels in the cell line, and immunohistochemistry to assess mucins in lung and trachea sections. 
Results: In vitro treatment of cells with LPS (10 μg/ml) or CSE (0.5, 1, 2.5 and 5%) alone, resulted in a statistically 
significant increase of MUC7 transcripts only with 1%CSE (3.2-fold). The combined CSE/LPS treatment resulted in a 
synergistic increase of MUC7 with 0.5%CSE/LPS (4.4 fold). MUC7 glycoprotein levels increased only minimally, the 
highest increase was seen with the 0.5%CSE/LPS combination treatment (1.3-fold). In vivo exposure of MUC7 transgenic 
mice to CS, LPS or CS/LPS combination resulted in significant increase in MUC7 transcripts only with LPS treatment (in 
both trachea and lung). Immunohistochemistry indicated variable increase in MUC7 glycoprotein with CS and LPS 
treatment, both in the trachea and lungs, but CS/LPS exposure appeared to yield the highest increase. 
Conclusion: In vitro, CSE and a combination of CSE/LPS treatment upregulated MUC7 gene transcription. In vivo, LPS 
upregulated MUC7 transcription, and a combination of CS/LPS appeared to increase MUC7 glycoprotein. 
Keywords: MUC7 expression, cigarette smoke, LPS, NCI-H292 cells, lungs, trachea. 
BACKGROUND 
  In the respiratory tract, mucus has an important 
protective function by entrapping inhaled foreign debris and 
bacteria, and clearing them from the airways by ciliary 
action [1]. Mucin production and secretion by specialized 
epithelial cells is a common mechanism used by mammals to 
protect the underlying mucosae against various injuries and 
pathogenic organisms. However, excess mucin production 
overwhelms the mucociliary clearance, resulting in defective 
mucosal defense and contributing to morbidity and mortality 
in related diseases. Acute challenges to the respiratory tract 
(including environment toxins, allergens, or infectious 
pathogens) activate lung inflammatory/immune response 
mediators. Some mediators initiate mucin hypersecretion by 
activating secretory granules of goblet cells in the surface 
epithelium and/or secretory cells in the submucosal gland 
[2]. A large number of biologically active molecules, such as 
cytokines, bacterial products, growth factors, differentiation 
agents and other factors, have been shown to regulate mucin  
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synthesis (in vitro and/or in vivo) in various cell types. The 
notion that inflammation activated mucin gene expression 
has had wide-reaching ramifications has emerged some time 
ago. It focused on the importance of mucin gene regulation 
in airway diseases such as cystic fibrosis, chronic obstructive 
pulmonary disease (COPD) and asthma [3]. 
  Smoking is among the major environmental health risk 
factors in the modern world affecting almost all the organ 
systems in the human body. Cigarette smoking is a major 
etiological factor in the pathogenesis of chronic obstructive 
pulmonary disease (COPD) [4]. Oxidative stress caused by 
cigarette smoking is thought to induce a chronic 
inflammatory response in the lungs, which results in the 
destruction of the alveolar cell walls and emphysema [5]. 
Moreover, increased oxidative stress can trigger 
proinflammatory cytokines, which are increased in the lungs 
of smokers and patients with COPD [6]. One of the previous 
studies have shown that cigarette smoke, along with other 
pathogenic factors, such tumor necrosis factor and LPS, can 
synergistically enhance respiratory MUC5AC induction [7]. 
  The human MUC7 gene encodes a small mucin 
glycoprotein that is secreted mainly by salivary glands, but 
the gene is also expressed in tracheobronchial system [8-10]. 64    The Open Respiratory Medicine Journal, 2010, Volume 4  Fan and Bobek 
MUC7 main functions are thought to be promoting the 
clearance of bacteria; MUC7 has been shown to interact with 
a variety of bacteria, including four strains of streptococci, 
Actinobacillus actinomycetemcomitans, Staphylococcus aur-
eus and Pseudomonas aeruginosa [11, 12], and to aid in 
mastication, speech and swallowing. In terms of MUC7 gene 
regulation, previous studies in our laboratory have shown 
that MUC7 transcript and glycoprotein product were 
increased in vitro upon treatment of airway epithelial cells 
A549 with a panel of cytokines (IL-1, IL-4, IL-13, TNF-, 
EGF), and in vivo upon the treatment of MUC7 transgenic 
mice with LPS [13]. 
  The study described in this manuscript was designed to 
further explore the regulation of MUC7 gene expression both 
in vitro and in vivo. Expression of human MUC5AC, mouse 
Muc5ac and mouse Muc10 (MUC7 ortholog) was assessed 
for comparative purposes. The results were compared and 
contrasted to the results of previous in vitro and in vivo 
studies. The in vitro experiments evaluated the effect of 
cigarette smoke extract (CSE), and CSE in combination with 
Pseudomonas aeruginosa lipopolysaccharide (LPS) on 
MUC7 expression in human lung mucoepidermoid 
carcinoma cell line NCI-H292. The in vivo experiments 
evaluated the effect of cigarette smoke (CS), and CS  and 
LPS combination on MUC7 expression utilizing MUC7 
transgenic mice. 
METHODS 
Preparation of Cigarette Smoke Extract 
  Aqueous cigarette smoke extract (CSE) was used to 
mimic the
 effects of cigarette smoke in the experiments with 
the cell line. Cigarette smoke of Research
  Cigarettes 1R1 
(University of Kentucky) was slowly bubbled through
  the 
Phenol Red–free RPMI 1640 medium containing 10 mM
 
HEPES. The suspension (pH adjusted to 7.4) was then 
filtered through a 0.22 μm pore filter to remove bacteria and 
large particles. The resulting CSE from one cigarette in 30 
ml of the media, considered to be 100%, was then diluted to 
different concentrations (using the same medium), and then 
applied to cell cultures within 30 min of preparation (either 
alone or in combination with LPS). 
Cell Culture 
  The human pulmonary mucoepidermoid carcinoma cell 
line NCI-H292 was obtained from the ATCC (American 
Type Culture Collection, Rockville, MD). The cells were 
grown in RPMI 1640 medium (GIBCO-BRL, Grand Island, 
NY) with 2 mM glutamine, 4.5 g/L glucose, 10 mM HEPES, 
1mM sodium pyruvate; supplemented with 10% fetal bovine 
serum (GIBCO-BRL), penicillin (100 units/ml), and 
streptomycin (50 mg/ml), and maintained at 37
oC in a 5% 
CO2 incubator. For different treatments, the cells were 
cultured in a 24-well plate. At about 70% confluency, the 
cells were exposed to LPS (10 μg/ml; an optimal dose, based 
on the dose-response curve determined previously [13]), or 
CSE (0.5%, 1%, 2.5%, 5%), or a combination of LPS and 
CSE. After 24 hours, the cells were harvested for RNA and 
cell lysate preparations, as described below. 
 
 
In Vivo Experiments with Mice 
  Animal experiments were approved by the Institutional 
Animal Care and Use Committee at the State University of 
New York at Buffalo. MUC7 transgenic mice and non-
transgenic mice littermates (produced in our animal facility), 
both males and females, were used in this experiment. All 
mice were 8 weeks old and had similar body weights (25 
g). The mice that were exposed to cigarette smoke (CS) were 
exposed to it for 4 consecutive days, but only during the 
daylight hours (8 hours, 1 cigarette per hour). The selected 
time-course of the study was based on the previous study 
with the rat model of LPS-induced inflammation with 
concurrent cigarette smoke inhalation [7], except the number 
of cigarettes per day was reduced to 8 (from 24 in the rat 
model). A peristaltic pump was put inside a chamber under 
the fume hood with the mice. The CS was combusted 
through the pump at a low speed. 
  The experiment included the following 4 groups with 5 
mice in each group. Group 1: Mice exposed to the CS only. 
Group 2: Mice exposed to CS/LPS. These mice were first 
exposed to CS for 24 hours, followed by instillation of LPS. 
Mice were anesthetized by injection of ketamine 
hydrochloride (80mg/kg) and xylazine hydrochloride 
(5mg/kg) to circumvent the cough reflex during instillation. 
The upper portion of trachea was surgically exposed (by 
making an incision in the skin and separating the thyroid 
gland overlying muscles and connecting tissues). A 
microsyringe carring a 25-gauge soft needle filled with 10μl 
(2.5μg) of LPS solution was inserted into the exposed 
trachea and the solution was injected into the lumen of 
mouse trachea. After injection, and a few hours of recovery, 
the mice were exposed to CS for 3 more days. Group 3: 
Mice exposed to LPS. These mice were first exposed to air 
for twenty-four hours, followed by instillation of LPS, and 3 
more days of exposure to air. Group 4: Mice exposed to air 
only. For all groups, on day 5, the mice were sacrificed and 
tissues (trachea and lungs) were collected for RNA isolation 
and immunohistochemistry analysis. 
RNA Preparation 
  Total RNA from cultured NCI-H292 cells and animal 
tissues was prepared using TRIzol reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s specification. 
The quality and quantity of RNA were determined 
spectrophotometrically. 
Reverse Transcription 
  Reverse transcriptions were carried out using Super 
Script™ III Reverse Transcriptase (Invitrogen, Carlsbad, 
CA) following the manufacturer’s instructions. Briefly, first-
strand cDNA was synthesized in a total volume of 20 l. 
Reactions contained total RNA (2 g), random hexamer 
primers (0.25 g), dNTPs (0.5 mM), rRNasin (200 units), 
SuperScript™ III Reverse Transcriptase (200 units) and 5 x 
first strand buffer (4 l). The reactions were incubated at 
65
oC for 5 mins, followed by 1 min incubation on ice, 10 
min at 25
oC, and 50 mins at 50
oC. Reactions were then 
inactivated at 70
oC for 15 mins. 
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Real-Time PCR 
  Quantitative real-time PCR was performed using Applied 
Biosystems 7500 Real Time PCR System (Foster City, CA) 
following the TaqMan Gene Expression Assay protocol 
(Applied Biosystems). TaqMan primers and probes for the 
human genes MUC7, MUC5AC and GAPDH (internal 
control), and the mice genes Muc5ac, Muc10 and Gapdh 
(internal control) were Pre-Developed (cataloged) by 
Applied Biosystems. The use of the human GAPDH and 
mouse Gapdh as an internal control was based on our 
previous findings that showed these to be optimal in our 
system over actin or tubulin internal controls. Each 50-μL 
reaction (in 96-well set-up) contained the following 
components: 20x TaqMan Gene Expression Assay mix (2.5 
μL), cDNA template + H2O (22.5 μL), 2x TaqMan Universal 
PCR Master Mix (25 μL). The TaqMan Gene Expression 
Assay mix contains FAM
TM dye-labeled TaqMan probe and 
2 unlabeled PCR primers (the primers were designed to span 
intron/exon boundaries to verify that PCR products were 
amplified from the cDNA). To optimize the reaction, we 
amplified serially diluted cDNA templates that were reverse 
transcribed from total RNA, and plotted the log of the 
abundance of target gene products against Ct (threshold 
cycle). PCR amplification was carried out under the control 
of SDS software (Sequence Detection Systems). The data 
was analyzed with Relative Quantification Study Document. 
The relative quantity of MUC7 or MUC5AC mRNA was 
normalized to human GAPDH, and Muc5ac or Muc10 
mRNA to mice Gapdh expression. The relative 
quantifications were calculated using  CT method. 
Cell Lysate Preparation and ELISA Assays 
  NCI-H292 cell lysates were prepared by dissolving the 
cells in radioimmunoprecipitation assay lysis buffer 
(Millipore Co, Billerica, MA). ELISA was performed with a 
Protein Detector ELISA kit (Kirkegaad and Perry Laboratory 
Inc, Gaithersburg, MD) following the manufacturer’s 
instructions. The primary MUC7 antibody (rabbit antisera) 
was prepared by Bio-Synthesis (Lewisville, TX); it is 
specific to a 15-mer peptide derived from MUC7 mucin 
glycoprotein (aa 39-53). The primary MUC5AC/Muc5ac 
antibody was purchased from AnaSpec, Inc. (San Jose, CA). 
Its reactivity includes human, mouse and rat. The secondary 
antibody was goat anti-rabbit IgG-alkaline phosphatase 
conjugate. The lysates (60μl) plus coating buffer (40μl, 
included in the kit) were pipetted into 96-well microtiter 
plates. Human saliva (60μl) plus coating buffer (40μl) was 
used as a positive control, and 100μl coating buffer was used 
as a negative control. The plate was read at 630 nm using 
ELISA Microplate reader with 630 filter. 
Immunohistochemistry 
  Prior to immunohistochemistry, each histological sample 
was incubated in 0.5 M sucrose in PBS overnight and 
cryosectioned (7μm). Immediately after cryosectioning, 
tissue sections were washed three times in PBS (10 min at 
RT) and incubated with a blocking agent (1% BSA, 10% 
goat serum, 0.1% Triton X-100 in PBS) for 2hrs at RT. 
Then, they were incubated for 1 hr at RT with monoclonal 
mouse anti-MUC7 antibody [14] and MUC5AC/Muc5ac 
monoclonal antibody (AnaSpec, Inc., Catalog# 53684;   
 
species reactivity includes human, mouse and rat). Both 
antibodies were diluted 1:1000 in the blocking agent. After 
washing three times with PBS (10 min RT), tissue sections 
were incubated for 2.5 hrs at RT with a fluorescent 
secondary goat anti-mouse Ig-G (Alexa Fluor 488, 
Molecular Probes, USA) diluted in 1% BSA, 10% goat 
serum in PBS (1:150). The sections were then washed three 
times in PBS (10 min each at RT), air dried for 10 min at RT 
and covered with a cover glass using an aqueous mounting 
medium (Immu-Mount, Thermo-Shandon, USA). 
Fluorescent pictures (200) were acquired by a digital 
camera (70 ms exposure time; SPOT RT-KE Diagnostic 
instruments Inc.), attached to a Nikon inverted fluorescent 
microscope (Nikon Eclipse TE2000-U). 
Statistical Analysis 
  Statistical analyses of real-time PCR and ELISA results 
were performed upon comparisons made between the treated 
group and the control group using the Student’s t-test. A p 
value of less than 0.05 was considered statistically 
significant. Data is expressed as mean + standard error (SE). 
RESULTS 
In Vitro Studies 
Effects of LPS, CSE and CSE/LPS on MUC7 (and 
MUC5AC) Gene Transcription 
  NCI-H292 cells were selected for these experiments 
since it was reported in the literature that these cells express 
LPS receptors [15, 16]. Quantitative real time RT-PCR was 
used to assess the steady-state MUC7 gene transcription. 
Expression of human MUC5AC, the high molecular weight 
respiratory mucin, shown previously to be upregulated by 
CSE, was also assessed for comparative purposes [7]. The 
results are shown in Fig. (1). 
  For MUC7 (Fig. 1A), a statistically significant level of 
induction (p value less than 0.05) was found with the 1% 
CSE treatment (3.2-fold, left panel) and with the 0.5% CSE 
plus LPS combination treatment (4.4-fold, right panel). The 
p  value less than 0.05 was also observed for 1% CSE 
compared with 0.5% CSE (left panel). For MUC5AC gene 
(Fig. 1B), the cell treatment with LPS alone resulted in the 
statistically significant increase of MUC5AC transcripts (6 
fold, left panel). The treatment with CSE alone resulted in 
some increase of MUC5AC transcripts with each 
concentration of CSE used, but none of the increases were 
statistically significant. On the other hand, the combination 
of 1% CSE with LPS showed a statistically significant 
increase of MUC5AC transcripts (11 fold, right panel). The 
treatment with 2.5% CSE and LPS resulted up to 23 fold 
increase in MUC5AC transcripts, but due to the large SD, 
there is no statistically significant difference compared to the 
untreated cells. The p value less than 0.05 was also observed 
for 1% CSE plus LPS group compared with 0.5% CSE plus 
LPS group. 
Effects of LPS, CSE and CSE/LPS on MUC7 (and 
MUC5AC) Glycoprotein Production 
  The levels of glycoproteins in the control and stimulated 
NCI-H292 cells were assessed by ELISA assay. Upon 
stimulation with the agents, both the MUC7 and MUC5AC  
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mucin glycoprotein levels increased only minimally: none of 
the increases were statistically significant (results not 
shown). The MUC7 increased the most with the 0.5% 
CSE/LPS combination treatment (1.3 fold), and MUC5AC 
with the 1% CSE/LPS stimulation (1.5 fold). The other 
treatments resulted in smaller increase or no increase in these 
mucin glycoproteins. 
In Vivo Studies 
Effect of LPS and CS on MUC7 (and Muc5ac and Muc10) 
Gene Transcription in MUC7 Transgenic Mice Tissues 
  For these studies, we utilized the previously generated 
MUC7 gene transgenic mice [17]. These mice carry the   
 
human MUC7 gene (~10 kb) with a 3 kb of the 5’- and a 3 
kb of the 3’-flanking sequences, totaling to a 16 kb of human 
genomic DNA. MUC7 transgene transcription in mice was 
assessed along with the endogenous mouse mucins, Muc5ac 
(high molecular weight tracheobronchial mucin) and Muc10 
(ortholog of human MUC7). The results are shown in Fig. 
(2). In the mice trachea (Fig. 2A), the statistically significant 
increase (p<0.05) of MUC7 transcription was observed only 
in the group stimulated with the LPS alone (2 fold); and of 
Muc5ac transcription in the groups stimulated with the LPS 
(2.5 fold), CS (2.5 fold), and CS/LPS (2.7 fold). In the mice 
lungs (Fig. 2B), the statistically significant increase was 
observed only with the MUC7 gene and only in the group of 
mice treated with LPS (2.1 fold). 
 
Fig. (1). Effect of CSE, LPS and CSE/LPS on mucin gene transcription in vitro, using human NCI-H292 cells. Total RNA was isolated 
from the control cells and treated cells and reversed transcribed. MUC7 expression (panel A) and MUC5AC expression (panel B) was 
determined by quantitative Real-Time PCR (qRT-PCR). The level of different mucin mRNA was normalized to GAPDH. Each bar 
represents the SD from three independent experiments. * indicates p < 0.05. LPS, lipopolysaccharide from P. aeruginosa, used at 
concentration of 10 μg/ml in all experiments (an optimal dose, determined by the dose-response curve; data not shown). CSE, cigarette 
smoke extract, used at several different concentrations, either alone or in combination with LPS, as indicated. Relative levels of mucin 
mRNA are expressed as fold of induction comparing to the control, untreated cells, set arbitrary at a value of 1. Regulation of Human MUC7 Mucin Gene Expression  The Open Respiratory Medicine Journal, 2010, Volume 4    67 
Effect of CS and LPS on MUC7 (and Muc5ac) 
Glycoprotein Production in MUC7 Transgenic Mice 
Tissues 
  In this regard, we performed immunohistochemistry (IHC) 
experiments with the mice trachea and lung tissue sections. In 
our previous study [13] we have determined by IHC which 
types of cells in trachea and lungs of MUC7 transgenic mice 
produce MUC7 glycoprotein. In trachea, MUC7 was localized 
within the serous cells of the submucosal glands, and in the 
lungs within the respiratory epithelium at the level of the 
bronchioles and within the stromal tissue. This study showed 
similar findings. The tissues of several mice were analyzed and 
representative results are shown in Fig. (3). The IHC data were 
not statistically analyzed and therefore are not quantitative. For 
MUC7 immunohistochemistry, a nontransgenic mice tissue was 
used as a negative control and the non-treated MUC7 transgenic 
mice tissue as a positive control. A visual examination of 
immunohistochemistry results from the untreated and treated 
animals showed the following: As expected, no detectable 
MUC7 glycoprotein was found in the non-transgenic mice 
tissue (Fig. 3A, B, Control(-)), and a positive MUC7 staining 
was found in the control, non-treated MUC7 transgenic mice 
tissue (Fig, 3A, B, Control(+)). Also, as expected, endogenous 
mouse Muc5ac was detected in the control, non-treated MUC7 
transgenic mice tissue (Fig. 3A, B, Control panels for Muc5ac). 
For the treated animals: In trachea (Fig. 3A), MUC7 
glycoprotein reactivity/production appeared to increase upon 
mice exposure to LPS alone or to CS alone, but the highest 
increase was seen upon exposure to the combination of 
CS/LPS; Muc5ac glycoprotein reactivity/production appeared 
to increase upon mice exposure to CS alone and a higher 
increase was again seen with a combination of CS/LPS. In the 
lungs (Fig. 3B), MUC7 glycoprotein reactivity seemed to 
increase upon stimulation with the CS alone, but a much greater 
increase was observed with the CS/LPS combination; Muc5ac 
increased reactivity in lungs is observed in the mouse stimulated 
with CS alone or LPS alone, and the reactivity increased slightly 
with the CS/LPS combination exposure. Collectively, these 
results indicated that upon exposure of mice to a combination of 
CS/LPS, a MUC7 glycoprotein reactivity/production seemed to 
increase considerably in both trachea and lung tissues, but 
Muc5ac increased mostly in trachea. 
DISCUSSION 
In Vitro Studies 
  The treatment of the NCI-H292 cells with P. aeruginosa 
LPS did not lead to increase of MUC7 transcription despite 
the fact that, as reported, these cells express TLR4 [15, 16] 
through which the bacterial LPS activate cells. In our 
 
Fig. (2). Effect of CS, LPS and CS/LPS on mucin gene transcription in vivo, using MUC7 transgenic mice. Total RNA was isolated 
from the untreated and treated mice tissue and reverse transcribed. Human MUC7, and mouse Muc5ac and Muc10 expression in trachea 
(panel A) and in lung (panel B) was determined by quantitative Real-Time PCR (qRT-PCR). The level of different mucin mRNA was 
normalized to mouse Gapdh. Each triangle point represents individual control or experimental mouse (n=5). The horizontal line represents 
the average expression of the particular mucin in each group of animals. The mice groups are: control (exposed to air), LPS (exposed to 
lipopolysaccharide), CS (exposed to cigarette smoke) and CS/LPS (exposed to combination of cigarette smoke and lipopolysaccharide). The 
significant increase in the levels of mucin gene expression in the tissues of treated versus untreated mice, or the p value <0.05 was found in 
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previous study, we showed that MUC7 transcription was 
also not increased by LPS treatment of the A549 lung 
carcinoma cell line, but it was increased in the primary 
normal human tracheobronchial epithelial (NHTBE) cells 
[13]. We attributed the lack of MUC7 induction by the LPS 
in the A549 cells to the lack of the LPS receptors, TLR4 (as 
determined by flow cytometric analysis by another group) 
[18], and the MUC7 induction in the primary cells to the 
presence of TLR4. However, it should be noted that the more 
recent studies using RT-PCR showed that A549 cells do 
express TLR4 [16, 19]. Thus it appears that these human 
airway epithelial cell lines, although extensively used for in 
vitro studies, have a weakness, i.e. expressing variable levels 
of TLR4 receptor. MUC5AC transcription in the NCI-H292 
cells, used in this study, increased significantly upon the LPS 
treatment (6-fold), and this finding is consistent with the 
previous studies using the same cell line [7, 20]. 
  The treatment of NCI-H292 cells with different doses of 
CSE resulted in a statistically significant increase in the level 
of MUC7 transcription only with the 1% dose (3.2 fold). For 
MUC5AC, a moderate increase was seen with the most CSE 
doses used, but none of the increases were statistically 
significant. The previous studies indicated that MUC5AC 
was upregulated by CSE in NCI-H292 cells [7] and further 
that cigarette smoke causes mucin overproduction via EGF 
receptor (EGFR) activation in airway epithelial cells in vitro 
and in vivo [21, 22]. 
  Regarding the question whether the MUC7 gene 
transcription can be enhanced by the LPS/CSE combination 
treatment in NCI-H292 cell line, we found that MUC7 
mRNA was statistically significantly increased only with the 
0.5% CSE/LPS treatment. In fact, the MUC7 transcript was 
increased by 4.4 fold, which represents a synergistic 
increase. However, 1% CSE/LPS treatment led to no MUC7 
transcription increase, and in fact the level was even lower 
than for the untreated, control cells, indicating that this 
combination lead to antagonistic effect, eliminating the 3.2-
fold increase achieved with 1% CSE. A suppression of 
MUC7 expression may not be due to potential toxicity of the 
combined stimuli, because stimulation of cells with 1% 
CSE/LPS treatment yielded 11-fold transcription increase of 
MUC5AC. This latter finding also represents a synergistic 
effect and it is in an agreement with the previous study, 
which demonstrated that co-stimulation with 1% CSE/LPS 
 
Fig. (3). Effect of CS, LPS and CS/LPS on mucin production in vivo, using MUC7 transgenic mice determined by 
immunohistochemistry. A representative results from tissues of several mice are shown. MUC7 and Muc5ac in trachea (panel A), and 
MUC7 and Muc5ac in lungs (panel B). Fluorescent (upper) and phase contrast (lower) pictures are shown for each tissue sample. For MUC7 
mucin, Control(-) and Control(+) were tissue samples from trachea or lung samples from the non-treated nontransgenic mice (not expressing 
human MUC7) and MUC7 transgenic mice (expressing MUC7), respectively. For Muc5ac mucin control, samples from trachea or lung from 
the non-treated MUC7 transgenic mice (these express Muc5ac) were used. Pictures (200) were acquired by a digital camera attached to a 
Nikon inverted fluorescent microscope. Hematoxylin-eosin staining (not shown) indicated the integrity of the tissue. 
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synergistically increased MUC5AC mucin transcription (15-
fold) in NCI-H292 cells [7]. The underlying mechanisms of 
synergy between the CSE and LPS are unclear, but the 
authors of the above study speculated that CSE acts at 
multiple levels to synergistically enhance mucin production. 
We have noticed a recent study that reported that CSE 
induced expression of TLR4 and LPS binding in another 
epithelial cell line, namely 16-HBE [23], and thus it is 
tempting to speculate that this could be one possible 
explanation for the observed synergy between the CSE and 
LPS treatment of NCI-H292 cells and the transcription of 
MUC7 and MUC5AC. 
  The CS, LPS, and the combination of CS/LPS treatment 
of the NCI-H292 cell line resulted only in a small increase in 
both MUC7 glycoprotein (maximum 1.3 fold with the 0.5% 
CSE/LPS treatment) and MUC5AC glycoprotein production 
(maximum 1.5 fold with the 1% CSE/LPS treatment; data 
not shown). Note, however, that both of these highest 
increases in glycoprotein production were achieved with the 
same combination of CSE/LPS treatment that yielded the 
synergistic increase of the MUC7 and MUC5AC transcripts, 
indicating some degree of correlation between transcription 
and glycoprotein production. Other studies, using the same 
cell line, reported elevation of MUC5AC glycoprotein upon 
CSE treatment, which appeared to increase in a dose 
dependent manner, from 1.3-2.5 fold [24] and from 2-3 fold 
[7], and with the combination of CSE/LPS treatment, 4-fold 
induction was seen [7]. 
In Vivo Studies 
  We chose to use CS rather than CSE for in vivo 
experiments in order to resemble the smoke exposure 
experience by smokers. Even though intranasal 
administration of CSE in vivo maybe more convenient, the 
study by Elliot et al. [25] showed that its resemblance to the 
CS exposure experience is not equivalent. CSE resulted in a 
heavier exposure to cigarette smoke components over the 
same treatment length. 
  Measuring induction of human MUC7 mRNA after 
treatment of MUC7 transgenic mice with LPS, CS or 
combination of LPS/CS showed statistically significant 
increase in MUC7 mRNA in both trachea and lung with LPS 
treatment only (Fig. 2). The two-fold increase of MUC7 
mRNA with the LPS treatment is consistent with our 
previous in vivo study [13]. Mouse Muc5ac transcript was 
found to statistically increase in trachea (but not in lungs) 
with all three treatments (LPS, CS, LPS/CS), compared to 
the control animals. On the other hand, the study [7] using a 
rat model showed no induction of rat muc5AC with LPS or 
CS alone, in either trachea or lungs; the induction was seen 
only with the combination of LPS/CS, in both trachea and 
lungs. 
  The levels of MUC7 or Muc5a glycoprotein reactivity/ 
production in the animal tissues using immunohisto-
chemistry in our study, and the level of total mucin content 
in the tracheobronchial lavage fluid measured by enzyme-
linked lectin assay by the investigators using the rat model 
[7], are hard to compare. Also, our immunohistochemistry 
results are not quantitative. Nevertheless, the exposure of 
animals to a combination of LPS/CS treatment seems to 
result in increased levels of MUC7 and Muc5ac mucin 
reactivity/production in our mouse model, and increased the 
total mucin levels in the rat model, as compared to the 
animals treated with CS or LPS alone. 
  The role of MUC7 and its regulation in different stages 
of different diseases is still not understood. MUC7 is a small, 
soluble, non-gel-forming mucin. Its main function is thought 
to be clearance of various bacteria and thus inhibition of 
bacterial colonization. It has been shown to interact in vitro 
with many oral and respiratory microorganisms, including P. 
aeruginosa [26]. Thus, the increased production of MUC7 
soluble mucin, seen upon exposure of mice to P. aeruginosa 
LPS/CS exposure shown in vivo by immunohistochemistry 
in this study, may reduce the viscosity of the mucus caused 
by overproduction of the large, gel forming mucins in the 
respiratory track. This increase in the soluble MUC7 may 
facilitate the mucocilliary clearance, and thus have a 
protective role in the respiratory track by maintaining an 
appropriate balance between detrimental and beneficial 
outcomes. 
CONCLUSIONS 
  1% CSE and 0.5% CSE/LPS treatment of the cell line 
resulted in statistically significant and synergistic increase of 
MUC7 transcript, respectively. The exposure of mice to CS, 
LPS or CS/LPS resulted in statistically significant increase in 
MUC7 transcripts in both trachea and lung with LPS only, 
and a variable increase of MUC7 glycoprotein, with the 
highest increase with CS/LPS. These results contributed to 
the understanding of the regulation of MUC7 expression by 
pathogenic factors, however, further studies are necessary in 
order to understand the mechanism of MUC7 regulation and 
its possible role in different stages of different diseases. The 
possible protective role of the increased soluble MUC7 in 
the respiratory tract induced by CS/LPS warrants further 
investigation. 
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